About NeOnc Technologies
NeOnc Technologies is a company based in Los Angeles (United States) founded in 2008. NeOnc Technologies has raised $18.74 million across 7 funding rounds from investors including NIH. The company has 4 employees. NeOnc Technologies operates in a competitive market with competitors including MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Qnovia, among others.
- Headquarter Los Angeles, United States
- Employees 4
- Stage Public
- SectorsHealthcare
- Website neonctech.com
- Social LinkedIn
- Legal Name Neonc Technologies Holdings, Inc.
- Annual Revenue$39.99 K (USD)-51.82as on Dec 31, 2025
- Net Profit-$62.15 M (USD)-422.3as on Dec 31, 2025
- EBITDA-$58.2 M (USD)-719.63as on Dec 31, 2025
- Total Equity Funding$18.74M (USD)
in 7 rounds
- Latest Funding Round$2.5M (USD), Grant
Aug 2025
- Investors
- Employee Count4
Funding Insights of NeOnc Technologies
NeOnc Technologies has successfully raised a total of $18.74M across 7 strategic funding rounds. The most recent funding activity was a Grant round of $2.5 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $18.74M
- Total Rounds 7
- Last Round Grant — $2.5M
- First Round $90,500
(Dec 2009)
- Investors Count 1
All 7 funding rounds of NeOnc Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2025 | $2.5M | Grant | – | – | |
| Jul 2024 | $18.34M | Series A | – | – | – |
| Feb 2022 | $50,000 | Seed | – | – | – |
| Feb 2013 | $24,750 | Seed | – | – | – |
| Aug 2012 | $150,000 | Seed | – | – | – |
| Dec 2010 | $78,500 | Seed | – | – | – |
| Dec 2009 | $90,500 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in NeOnc Technologies
NeOnc Technologies has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States |
Investor details for NeOnc Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of NeOnc Technologies
NeOnc Technologies is a publicly listed company on the NASDAQ with ticker symbol NTHI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date26 Mar 2025
- Listed onNASDAQ: NTHI
- Listed entityNeOnc Technologies Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS64051A1016
- Share price$2.53 (-6.64% on the day) · 2026-10-08
- Market capitalisation$72.9M
- EPS (diluted, trailing year)$-2.12
- Volume (last session)255,561
Financials of NeOnc Technologies
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $39,990 | -$62.1M | -$58.2M |
| 2024 | $83,000 | -$11.9M | -$7.1M |
| 2023 | $70,460 | -$14.9M | -$8.1M |
| 2022 | $20,000 | -$3.0M | -$2.8M |
| 2021 | – | -$3.4M | -$3.3M |
Detailed financial statements for NeOnc Technologies
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of NeOnc Technologies
4 dated milestones of NeOnc Technologies across 17 years, from founding to its latest funding, stage changes and deals.
- Founded NeOnc Technologies is founded.
- Funding First funding round of $90K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $2.5M.
Competitors of NeOnc Technologies
NeOnc Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, OptiNose, Impel NeuroPharma, Alexza and Qnovia, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mannkindcorp.com | 1991 | Los Angeles, United States | $50M | 322 | Developer of small-molecule drugs | |
| optinose.com | 2000 | Morrisville, United States | $120.5M | 132 | Developer of smart devices for nasal drug delivery | |
| impelnp.com | 2008 | Seattle, United States | $126.83M | 158 | Intranasal delivery technology for CNS diseases is developed. | |
| alexza.com | 2000 | Mountain View, United States | $97M | 72 | Developer of products for the treatment of acute and intermittent conditions | |
| qnovia.com | 2018 | Richmond, United States | $38.12M | – | Inhaled drug delivery devices are developed for pharmaceuticals. | |
| iconovo.se | 2013 | Lund, Sweden | $3.56M | – | Inhalation devices for medical applications are developed by Iconovo. | |
| aerami.com | 2010 | Durham, United States | $151.1M | – | Therapeutics for cardiopulmonary diseases are developed using inhaled therapies. | |
| nobhilltherapeutics.com | 2016 | Albuquerque, United States | $3.67M | – | Dry powder nebulizer is developed for targeted lung drug delivery. | |
| beyondair.net | 2011 | Garden, United States | – | – | Developer of device for treating respiratory conditions | |
| nebuflow.com | 2019 | Glasgow, United Kingdom | $7.97M | – | Aerosol delivery platform technology is developed for medical applications. |
Detailed competitors of NeOnc Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neonc Technologies
Complete news archive for NeOnc Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to NeOnc Technologies
10 companies that operate in the same segment as NeOnc Technologies (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about NeOnc Technologies
NeOnc Technologies was founded in 2008 and raised its 1st funding round 1 year after it was founded.
NeOnc Technologies is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
NeOnc Technologies is a funded company, having raised a total of $18.74M across 7 funding rounds to date. The company's 1st funding round was a Seed of $90.5K, raised on Dec 2009.
NeOnc Technologies has 4 employees.
Annual revenue of NeOnc Technologies is $39.99K as on Dec 31, 2025.
NeOnc Technologies was founded in 2008 in Los Angeles, United States, within the biotechnology sector. Intranasal inhalation methods using perillyl alcohol are developed for treating malignant brain cancers such as gliomas. Worldwide rights to NEO100, a purified form of perillyl alcohol, have been secured. FDA approval for clinical trials in patients with recurrent Grade 4 glioma has been obtained, focusing on pharmaceutical therapeutics delivery.
NeOnc Technologies's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.
Yes, NeOnc Technologies is publicly traded on NASDAQ under the ticker symbol NTHI.
NeOnc Technologies has 1 investor. Key investors include NIH.
NeOnc Technologies operates through Neonc Technologies, Inc..